Con Panousis serves as the Vice President of Drug Discovery at CSL, steering the development of novel biotherapies. His career at CSL has spanned multiple senior roles, including leadership in sa-mRNA development, molecular biology, and antibody technologies. He is a prolific inventor, named on numerous patents for innovative therapeutics.
He has a strong background in academic research, having co-authored scientific papers on molecular biology and biochemistry. His work reflects a deep interest in the intersection of academic discovery and industrial application to solve complex medical challenges.
Unique fact: Con Panousis co-authored a scientific paper while at La Trobe University, showcasing his early and continued commitment to foundational research.
Con Panousis
Vice President, Drug Discovery at CSL
Australia
Overview
Topics They Care About
Drug Discovery
As Vice President of Drug Discovery, he leads CSL's efforts in identifying and advancing a pipeline of novel biologic medicines.
Antibody Engineering
He is an inventor on multiple patents for novel antibodies, including treatments for hereditary angioedema and atherosclerosis, highlighting his deep expertise in the field.
Factor XIIa Inhibition
He has been integral to the development of Garadacimab, a monoclonal antibody targeting activated factor XII (FXIIa) for treating hereditary angioedema.
Media Appearances
Con has no verified media appearances
Work History
8-2025
Vice President, Drug Discovery at CSL
12-2024 - 10-2025
Vice President, Research Australia at CSL
12-2022 - 12-2024
Executive Director, sa-mRNA Development at CSL
10-2018 - 12-2022
Senior Director - Head of Molecular Biology at CSL
2-2002 - 10-2018
Director - Antibody Technologies at CSL
Education
Education details unavailable from La Trobe University
More Information
Social Presence :
Prographics :
Exp : 24
Location : Australia
Job Level : Senior
Designation : Vice President, Drug Discovery at CSL
